Interestingly, the tumor cells in two TNBC groups displayed different expression patterns of the critical immunotherapeutic targets, such as PD-1/L1, CTLA4, CD47, CDK4/6, PARP1/2 and DDR1/2 (Fig. 7A; Additional file 14: Table S7). This evidence concerns the gene PARP1 and neoplasm.